INMARK_supports_early_treatment_in_IPF

INMARK ® results suggest prompt treatment of IPF with antifibrotics to slow disease progressionINMARK ® trial results published in The Lancet Respiratory Medicine1Treatment with nintedanib versus placebo for 12 weeks did not affect the rate of change of the biomarker CRPM but was associated with a reduced rate of decline in forced vital capacity (FVC)1Patients with well-preserved lung function showed equivalent amount of decline in FVC to patients with worse baseline lung function in earlier studies1
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news